

TABLE 3 Hematologic Treatment Regimens and Adverse Events

	N (%)
Medication Regimen	
ASA	22 (73%)
LMWH Prophylaxis	7 (23%)
LMWH Treatment	11 (37%)
Unfractionated Heparin	2 (8%)
Apixaban	12 (40%)
Antiplatelet + Anticoagulant*	17 (57%)
Adverse Events	
Thrombotic Event	0 (0%)
Bleeding Event	7 (23%)
Major	0 (0%)
Non-major	2 (7%)
Minor	5 (17%)

*Numbers represent numbers (%) for categorical variables, * denotes patients treated with an antiplatelet agent + any anticoagulant at any point during their treatment for MIS-C. ASA = aspirin, LMWH = low molecular weight heparin.*